Sarepta

Completing steps towards success checkmark on cubes symbolizing progress
Biotech

Sarepta shares safety update on DM1 RNA med

A drug safety group has delivered a positive review for an investigational siRNA being studied in a phase 1/2 trial for type 1 myotonic dystrophy.
Gabrielle Masson Nov 24, 2025 4:00pm
Stock exchange concept

Sarepta sells 9M Arrowhead shares for $174M cash

Aug 13, 2025 5:44pm
sarepta building
Favicon Fierce Pharma

FDA backtracks on Sarepta's gene therapy Elevidys in DMD

Jul 28, 2025 6:02pm
timer sand clocks time

Arrowhead meets $100M milestone, awaits Sarepta payment

Jul 28, 2025 3:10pm
FDA
Favicon Fierce Pharma

FDA eyeing study requirements to confirm Elevidys safety: report

Jul 24, 2025 3:12pm
An artists impression of DNA The DNA appears to be made up of glowing orbs and appears on a blue background

FDA slaps clinical hold across all of Sarepta’s LGMD trials

Jul 21, 2025 11:36am